Nastaran Barati

2.2k total citations
23 papers, 542 citations indexed

About

Nastaran Barati is a scholar working on Molecular Biology, Immunology and Radiology, Nuclear Medicine and Imaging. According to data from OpenAlex, Nastaran Barati has authored 23 papers receiving a total of 542 indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Molecular Biology, 9 papers in Immunology and 8 papers in Radiology, Nuclear Medicine and Imaging. Recurrent topics in Nastaran Barati's work include Immunotherapy and Immune Responses (9 papers), RNA Interference and Gene Delivery (8 papers) and Monoclonal and Polyclonal Antibodies Research (8 papers). Nastaran Barati is often cited by papers focused on Immunotherapy and Immune Responses (9 papers), RNA Interference and Gene Delivery (8 papers) and Monoclonal and Polyclonal Antibodies Research (8 papers). Nastaran Barati collaborates with scholars based in Iran, Canada and Italy. Nastaran Barati's co-authors include Amirhossein Sahebkar, Atefeh Arab, Amir Abbas Momtazi‐Borojeni, Mahmoud Reza Jaafari, Javad Behravan, Atefeh Razazan, Fatemeh Mosaffa, Ali Badiee, Amin Reza Nikpoor and Muhammed Majeed and has published in prestigious journals such as SHILAP Revista de lepidopterología, PLoS ONE and Scientific Reports.

In The Last Decade

Nastaran Barati

21 papers receiving 526 citations

Peers

Nastaran Barati
Mary E. Neville United States
Elżbieta Pajtasz‐Piasecka Poland
Yanhong Chu China
Mitra Ahmadi France
Matthew E. Griffin United States
Mingming Gao China
Kaitlyn D. LaCourse United States
Noemi Poerio Italy
Mohammad M. Farajollahi Iran
Ling Lin China
Mary E. Neville United States
Nastaran Barati
Citations per year, relative to Nastaran Barati Nastaran Barati (= 1×) peers Mary E. Neville

Countries citing papers authored by Nastaran Barati

Since Specialization
Citations

This map shows the geographic impact of Nastaran Barati's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Nastaran Barati with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Nastaran Barati more than expected).

Fields of papers citing papers by Nastaran Barati

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Nastaran Barati. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Nastaran Barati. The network helps show where Nastaran Barati may publish in the future.

Co-authorship network of co-authors of Nastaran Barati

This figure shows the co-authorship network connecting the top 25 collaborators of Nastaran Barati. A scholar is included among the top collaborators of Nastaran Barati based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Nastaran Barati. Nastaran Barati is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
3.
Tanzadehpanah, Hamid, et al.. (2023). In vitro anticancer activity of hydatid cyst fluid on colon cancer cell line (C26). SHILAP Revista de lepidopterología. 24(1). 10 indexed citations
4.
Maghsood, Amir Hossein, et al.. (2023). Dimedone nanoparticle as a promising approach against toxoplasmosis: In vitro and in vivo evaluation. Biomedicine & Pharmacotherapy. 166. 115356–115356.
5.
Barati, Nastaran, et al.. (2022). Potential therapeutic effects of Ivermectin in COVID-19. Experimental Biology and Medicine. 247(15). 1388–1396. 2 indexed citations
6.
Barati, Nastaran, Amin Reza Nikpoor, Fatemeh Mosaffa, et al.. (2021). AE36 HER2/neu-derived peptide linked to positively charged liposomes with CpG-ODN as an effective therapeutic and prophylactic vaccine for breast cancer. Journal of Drug Delivery Science and Technology. 67. 102904–102904. 7 indexed citations
7.
Momtazi‐Borojeni, Amir Abbas, Atefeh Razazan, Mercedeh Mansourian, et al.. (2020). Preparation of nanoliposomes containing HER2/neu (P5+435) peptide and evaluation of their immune responses and anti-tumoral effects as a prophylactic vaccine against breast cancer. PLoS ONE. 15(12). e0243550–e0243550. 15 indexed citations
8.
Khazaei, Salman, et al.. (2020). Cryptosporidium animal species in Iran: a systematic review and meta-analysis. Tropical Medicine and Health. 48(1). 97–97. 13 indexed citations
9.
Barati, Nastaran, Amir Abbas Momtazi‐Borojeni, Atefeh Arab, et al.. (2019). P435 HER2/neu-derived peptide conjugated to liposomes containing DOPE as an effective prophylactic vaccine formulation for breast cancer. Artificial Cells Nanomedicine and Biotechnology. 47(1). 664–672. 29 indexed citations
10.
Razazan, Atefeh, Roderick Slavcev, Nastaran Barati, et al.. (2019). Lambda bacteriophage nanoparticles displaying GP2, a HER2/neu derived peptide, induce prophylactic and therapeutic activities against TUBO tumor model in mice. Scientific Reports. 9(1). 2221–2221. 31 indexed citations
11.
Barati, Nastaran, Atefeh Razazan, Roderick Slavcev, et al.. (2018). Immunogenicity and antitumor activity of the superlytic λF7 phage nanoparticles displaying a HER2/neu-derived peptide AE37 in a tumor model of BALB/c mice. Cancer Letters. 424. 109–116. 26 indexed citations
12.
Arab, Atefeh, Amir Abbas Momtazi‐Borojeni, Nastaran Barati, et al.. (2018). Preparation of nanoliposomes linked to HER2/neu‐derived (P5) peptide containing MPL adjuvant as vaccine against breast cancer. Journal of Cellular Biochemistry. 120(2). 1294–1303. 17 indexed citations
13.
Arab, Atefeh, et al.. (2018). The viral approach to breast cancer immunotherapy. Journal of Cellular Physiology. 234(2). 1257–1267. 27 indexed citations
14.
Arab, Atefeh, Javad Behravan, Atefeh Razazan, et al.. (2017). A nano-liposome vaccine carrying E75, a HER-2/neu-derived peptide, exhibits significant antitumour activity in mice. Journal of drug targeting. 26(4). 365–372. 38 indexed citations
15.
Razazan, Atefeh, Javad Behravan, Atefeh Arab, et al.. (2017). Conjugated nanoliposome with the HER2/neu-derived peptide GP2 as an effective vaccine against breast cancer in mice xenograft model. PLoS ONE. 12(10). e0185099–e0185099. 46 indexed citations
16.
Arab, Atefeh, Roderick Slavcev, Atefeh Razazan, et al.. (2017). Lambda phage nanoparticles displaying HER2-derived E75 peptide induce effective E75-CD8+ T response. Immunologic Research. 66(1). 200–206. 28 indexed citations
17.
Barati, Nastaran, Amin Reza Nikpoor, Atefeh Razazan, et al.. (2017). Nanoliposomes carrying HER2/neu-derived peptide AE36 with CpG-ODN exhibit therapeutic and prophylactic activities in a mice TUBO model of breast cancer. Immunology Letters. 190. 108–117. 24 indexed citations
18.
Shahabipour, Fahimeh, Nastaran Barati, Thomas P. Johnston, et al.. (2017). Exosomes: Nanoparticulate tools for RNA interference and drug delivery. Journal of Cellular Physiology. 232(7). 1660–1668. 96 indexed citations
19.
Teymouri, Manouchehr, Nastaran Barati, Matteo Pirro, & Amirhosein Sahebkar. (2016). Biological and pharmacological evaluation of dimethoxycurcumin: A metabolically stable curcumin analogue with a promising therapeutic potential. Journal of Cellular Physiology. 233(1). 124–140. 35 indexed citations
20.
Makhmalzadeh, Behzad Sharif, et al.. (2010). Development of Solid lipid nanoparticles as Eschar delivery system for Nitrofurazone Using Taguchi Design Approach. International Journal of Research in Pharmaceutical Sciences. 1(4). 466–472. 6 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Mary E. Neville Breakdown of academic impact, for papers by Elżbieta Pajtasz‐Piasecka Breakdown of academic impact, for papers by Yanhong Chu Breakdown of academic impact, for papers by Mitra Ahmadi Breakdown of academic impact, for papers by Matthew E. Griffin Breakdown of academic impact, for papers by Mingming Gao Breakdown of academic impact, for papers by Kaitlyn D. LaCourse Breakdown of academic impact, for papers by Noemi Poerio Breakdown of academic impact, for papers by Mohammad M. Farajollahi Breakdown of academic impact, for papers by Ling Lin
Rankless by CCL
2026